from Yahoo Finance https://ift.tt/2UrSn8K
-
Latest Ethereum price and analysis (ETH to USD)
-
3 high quality ASX dividend shares you can buy today
While the Australian economy is faring a lot better than many expected during the pandemic, I’m still of the belief that rates will remain lower for longer.
Barring a spike in inflation, I suspect the Reserve Bank will keep rates at 0.25% until at least 2022, but possibly longer.
In light of this, I think dividend shares remain the best way to generate a passive income. But which dividend shares should you buy? Three that I rate highly are listed below:
BHP Group Ltd (ASX: BHP)
The first dividend share I would consider buying is BHP. I believe the Big Australian would be a top option for investors due to its world class operations and favourable commodity prices. This is particularly the case with its iron ore operations, which are benefitting greatly from a surge in the price of the steel making ingredient. I expect BHP to generate significant free cash flows in the near term. And with its balance sheet in such a strong position, the majority of this free cash flow is likely to be returned to shareholders. I estimate that the mining giant’s shares currently provide investors with a forward fully franked ~5% dividend yield.
VanEck Vectors Australian Banks ETF (ASX: MVB)
Another dividend share to consider is the VanEck Vectors Australian Banks exchange traded fund. I think it is a great option for investors that are looking to invest in the banking sector, but aren’t sure which bank to buy. This is because this exchange traded fund gives investors exposure to all of the big four banks. It is also invested in Australia’s regional banks and investment bank Macquarie Group Ltd (ASX: MQG). Predicting the dividends the banks will pay in FY 2021 is tricky, but I would expect a yield of at least 5% from this exchange traded fund.
Wesfarmers Ltd (ASX: WES)
A final dividend share to consider buying is Wesfarmers. I’m a big fan of the conglomerate due to its strong businesses and their positive long term outlooks. Combined with its mountain of cash, which is likely to be used for acquisitions in the near future, I believe Wesfarmers is well-placed to grow its earnings and dividends at a solid rate over the next decade. This could make it a great long term option. At present I estimate that its shares offer a fully franked 3.7% FY 2021 dividend yield.
NEW: Expert names top dividend stock for 2020 (free report)
When our resident dividend expert Edward Vesely has a stock tip, it can pay to listen. After all, he’s the investing genius that runs Motley Fool Dividend Investor, the newsletter service that has picked huge winners like Dicker Data (+92%), SDI Limited (+53%) and National Storage (+35%).*
Edward has just named what he believes is the number one ASX dividend stock to buy for 2020.
This fully franked “under the radar” company is currently trading more than 24% below its all-time high and paying a 6.7% grossed-up dividend.
The name of this dividend dynamo and the full investment case is revealed in this brand new free report.
But you will have to hurry — history has shown it can pay dividends to get in early to some of Edward’s stock picks, and this dividend stock is already on the move.
More reading
- 5 things to watch on the ASX 200 on Tuesday
- Want high-paying dividends? Try Wesfarmers shares and these 2 other ASX options
- Where I’d invest $2,500 in ASX shares today
- Top brokers name 3 ASX 200 shares to buy next week
- How to replace your entire wage with dividends
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool Australia owns shares of Wesfarmers Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post 3 high quality ASX dividend shares you can buy today appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3f4Slvq
-
These are the 10 most shorted ASX shares
At the start of each week I like to look at ASIC’s short position report in order to find out which shares are being targeted by short sellers.
This is because I believe it is worth keeping a close eye on short interest levels as high levels can sometimes be a sign that something isn’t quite right with a company.
With that in mind, here are the 10 most shorted shares on the ASX this week according to ASIC:
- Myer Holdings Ltd (ASX: MYR) continues to be the most shorted share on the ASX despite another reduction in its short interest to 13.6%. It appears as though traders believe the pandemic has hastened the structural decline of department stores.
- Speedcast International Ltd (ASX: SDA) has short interest of 13.2%. This communications satellite technology provider’s shares remain suspended while it declares itself bankrupt.
- Super Retail Group Ltd (ASX: SUL) has seen its short interest remain flat at 10.9%. A number of this retail group’s brands look likely to have been impacted greatly by the pandemic. This could mean soft results and lower dividends in FY 2020 and FY 2021.
- Galaxy Resources Limited (ASX: GXY) has seen its short interest slide to 10.7%. Short sellers were closing their positions despite Chinese lithium prices tumbling to their lowest levels of the year last week.
- Webjet Limited (ASX: WEB) has jumped into the top ten with short interest of 9.7%. Traders may believe the online travel agent’s shares are overvalued after a strong rebound. Especially given the dilution caused by its capital raising.
- Orocobre Limited (ASX: ORE) has seen its short interest slide to 9.4%. This lithium miner’s shares were strong performers last week, possibly due to short sellers closing positions. Its shares have been hammered in recent times due to a collapse in lithium prices.
- Clinuvel Pharmaceuticals Limited (ASX: CUV) has seen its short interest rise to 9.3%. Traders may be targeting the biopharmaceutical company on the belief that its outlook doesn’t justify the lofty valuation its shares trade on.
- Nearmap Ltd (ASX: NEA) has seen its short interest edge higher to 9.3%. Unfortunately for short sellers, this aerial imagery technology company’s shares have been racing higher in recent weeks after a positive market update.
- Pilbara Mineral Ltd (ASX: PLS) has short interest of 9.2%, which is down slightly week on week. Pilbara is another lithium miner which experienced a decline in short interest last week. Short sellers may believe the worst is over for the industry.
- JB Hi-Fi Limited (ASX: JBH) has seen its short interest fall week on week to 9%. It appears as though some short sellers have been closing positions in response to the retailer’s solid sales performance during the pandemic.
Finally, instead of those most shorted shares, I would buy the exciting shares recommended below…
We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.
And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!
* Extreme Opportunities returns as of June 5th 2020
More reading
- 3 quality ASX 200 shares to buy and hold until at least 2030
- These were the best performers on the ASX 200 last week
- Will the Qantas share price crash back to Earth?
- ASX 200 rises 0.8%, travel shares fly higher
- The latest ASX 200 stocks to be upgraded to “buy” amid the recession
James Mickleboro owns shares of Galaxy Resources Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Nearmap Ltd. The Motley Fool Australia owns shares of and has recommended Super Retail Group Limited and Webjet Ltd. The Motley Fool Australia has recommended Nearmap Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post These are the 10 most shorted ASX shares appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3dJ5k5u
-
5 things to watch on the ASX 200 on Tuesday
On Friday the S&P/ASX 200 Index (ASX: XJO) finished a very positive week with a small gain. The benchmark index rose 0.1% to 5,998.7 points.
Will the market be able to build on this on Tuesday? Here are five things to watch:
ASX 200 to surge higher.
The ASX 200 looks set to start the week with a very strong gain after U.S. markets charged notably higher on Friday and Monday night. According to the latest SPI futures, the benchmark index is expected to open the week 147 points or 2.45% higher this morning. Overnight on Wall Street the Dow Jones jumped 1.7%, the S&P 500 stormed 1.2% higher, and the Nasdaq index rose 1.1%. The Dow Jones is up 4.9% over the last two trading days after stronger than expected U.S. jobs data.
Oil prices tumble lower.
Energy producers including Santos Ltd (ASX: STO) and Woodside Petroleum Limited (ASX: WPL) could come under pressure after oil prices tumbled lower overnight. According to Bloomberg, the WTI crude oil price fell 3.4% to US$38.21 a barrel and the Brent crude oil price dropped 3.5% to US$40.79 a barrel. Traders were selling oil after Saudi Arabia revealed that it would not extend its production cuts.
Free childcare to end next month.
The G8 Education Ltd (ASX: GEM) share price will be on watch on Tuesday after the Federal Government revealed plans to end its free childcare scheme in July. The government also intends to end the JobKeeper payment for workers in the sector. It will reintroduce the Child Care Subsidy in its place.
Gold price higher.
Gold miners including Newcrest Mining Limited (ASX: NCM) and Northern Star Resources Ltd (ASX: NST) will be on watch after a mixed couple of trading days. After tumbling notably lower on Friday, the gold price rebounded on Monday night. According to CNBC, the spot gold price rose 1.35% to US$1,705.40 an ounce.
Iron ore miners on watch.
BHP Group Ltd (ASX: BHP), Fortescue Metals Group Limited (ASX: FMG), and Rio Tinto Limited (ASX: RIO) could push higher again today after iron ore prices jumped. The spot iron ore price stormed over 5% on Monday and is now up to US$105 a tonne mark. All three of these miners are generating significant free cash flows from their operations with prices at these levels.
We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.
And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!
* Extreme Opportunities returns as of June 5th 2020
More reading
- 2 strong ASX dividend shares to bolster your income
- Want high-paying dividends? Try Wesfarmers shares and these 2 other ASX options
- How to build a $20,000 passive income with ASX shares
- Where I’d invest $2,500 in ASX shares today
- Top brokers name 3 ASX 200 shares to buy next week
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post 5 things to watch on the ASX 200 on Tuesday appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/30jHZ6E
-
Is Immunomedics, Inc. (IMMU) Going to Burn These Hedge Funds?
In this article you are going to find out whether hedge funds think Immunomedics, Inc. (NASDAQ:IMMU) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]
from Yahoo Finance https://ift.tt/37a3CYz
-
Why Facebook (FB) is Expected to Grow Sales at a Stellar Rate
Diamond Hill Capital recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Diamond Hill Small Cap Fund posted a return of -36.17% for the quarter, underperforming its benchmark, the Russell 2000 Index which returned -30.61% in the same quarter. You should check out Diamond Hill Capital's top 5 […]
from Yahoo Finance https://ift.tt/2ALRsJk
-
Sarepta Gene Therapy Win Helps to Validate Broader Platform
(Bloomberg) — Data on Sarepta Therapeutics Inc.’s experimental gene therapy for a rare type of muscular dystrophy showed that patients receiving a higher dose of the medicine saw greater benefits than those receiving a lower dose, delivering another early-stage win for the drug developer.Three patients with limb-girdle muscular dystrophy Type 2E who got the high dose of Sarepta’s SRP-9003 produced greater levels of the protein beta-sarcoglycan. While patients with the progressive and debilitating muscle-wasting disease normally make very little or none of the protein, the three children showed an average protein expression that was 62% of normal, topping 36% seen at the lower dose, when using a standard analysis called Western Blot.“We see a dose-dependent increase in expression and we see good tolerability across these kids in both the first and second cohort,” Chief Executive Doug Ingram said in an interview.All three patients in the early-stage study saw an average reduction in the enzyme that the muscle releases when it’s being damaged, known as CK, of 89% after 90 days. Ingram called the reduction in enzyme levels “encouraging.” The three patients also showed significant expression of alpha-sarcoglycan, another integral protein.Shares of Cambridge, Massachusetts-based Sarepta rallied as much as 4.7% at 9:31 a.m. in New York Monday, bringing its 2020 gain to 18%. RBC Capital Markets analyst Brian Abrahams advised clients to continue buying shares as the results help provide “clear differentiation” of Sarepta’s gene therapy platform compared to peers.Sarepta said in a slideshow that one patient had a serious case of dehydration that was a result of vomiting three days after receiving the one-time infusion. The side effects were resolved two days after treatment with a pair of nausea and vomiting medicines and intravenous fluids. Management brushed aside any concern for the side effects, saying it’s not uncommon for patients to have nausea after receiving a gene therapy.Ingram highlighted that none of the six patients treated saw a decrease in platelet counts that were outside of normal or any signals of complement activation. “That has been, for other therapies using different vectors, a very significant issue and in fact others have been put on clinical hold as a result of these very serious problems,” he said.While the opportunity in this rare disease is much smaller than the company’s leading program in Duchenne muscular dystrophy, Wall Street will likely be pleased with the update as it further validates Sarepta’s gene therapy platform. Coming into the data, analysts including Mizuho’s Difei Yang were looking for a solid safety profile as well as a clear increase in benefit at the higher dose.Sarepta also said three patients who received the lower dose of SRP-9003 had improved function one year after treatment.The company plans to select the final dose for a registrational trial in coming months as it continues to discuss trial designs with regulators around the world.When asked if there was interest in studying a higher dose of the gene therapy, Ingram said “we’re getting to the top of what one could reasonably expect.”The update comes less than a month after underwhelming data from competitor Pfizer Inc.’s Duchenne muscular dystrophy gene therapy sent shares of Sarepta to a nine-month high.(Updates with share movement and analyst commentary in fifth paragraph, adds chart)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
from Yahoo Finance https://ift.tt/2Yb3UdD
-
Astrazeneca, Gilead reportedly eyed merger
Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Anjalee Khemlani discuss a possible merger between Astrazeneca and Gilead Sciences. from Yahoo Finance https://ift.tt/2MBOIAV
-
Editors resign at New York Times and Philadelphia Inquirer
An editor at both the New York Times and Philadelphia Inquirer chose to resign after facing backlash over controversial headlines. Yahoo Finance’s Emily McCormick breaks down the details. from Yahoo Finance https://ift.tt/3h8WcJq
-
Amicus Therapeutics, Inc. (FOLD): Hedge Funds Folding Their Hands
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
from Yahoo Finance https://ift.tt/37bYva2